Solvay Cilansetron Irritable Bowel Safety Trial Size Reflects FDA Concerns
Executive Summary
Solvay's proposed 1,000-patient pivotal safety trial for the irritable bowel syndrome drug cilansetron reflects FDA's concern about the size of the safety database for IBS therapies.
You may also be interested in...
Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”
Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy
Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”
Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy
Novartis Expects Zelnorm U.S. Approval Despite EU Filing Withdrawal
Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.